ZLDPY (Zealand Pharma AS) Net Income (Continuing Operations): $-14.76 Mil (TTM As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLDPY Zealand Pharma AS ZLDPY
42 GF Score
Price $8.67
GF Value $358.32
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Zealand Pharma AS Net Income (Continuing Operations)?

Zealand Pharma AS ZLDPY -2.03% 42 Net Income (Continuing Operations) is $-14.76 Mil as of Jun. 2017. GuruFocus rates ZLDPY with a GF Score™ of 42/100 and a GF Value™ of $358.32 (Possible Value Trap). The stock has 5 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Zealand Pharma AS's Net Income (Continuing Operations) for the three months ended in Jun. 2017 was $-13.96 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2017 was $-14.76 Mil.

Zealand Pharma AS  (OTCPK:ZLDPY) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Zealand Pharma AS Net Income (Continuing Operations) Related Terms

Zealand Pharma AS Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Net Income (Continuing Operations) Chart

Zealand Pharma AS Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.31 -32.76 -11.56 -16.94 -22.87

Zealand Pharma AS Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.87 -4.64 7.65 -3.79 -13.96
ZLDPY
42GF Score
Zealand Pharma AS ZLDPY
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-14.76 Mil mean?
Zealand Pharma AS (ZLDPY) has a Net Income (Continuing Operations) of $-14.76 Mil as of Jun. 2017. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's Net Income (Continuing Operations) too high?
Zealand Pharma AS's current Net Income (Continuing Operations) is $-14.76 Mil. Overall, Zealand Pharma AS has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Net Income (Continuing Operations) compare to VRTX and REGN?
Zealand Pharma AS's Net Income (Continuing Operations) of $-14.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current Net Income (Continuing Operations) is $-14.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (ZLDPY) is currently considered Possible Value Trap. The stock's GF Value™ is $358.32, compared to a current price of $8.67 — trading 97.6% below its estimated fair value. The current Net Income (Continuing Operations) is $-14.76 Mil. Zealand Pharma AS's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPY), the current Net Income (Continuing Operations) is $-14.76 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (ZLDPY) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $8.67 is trading 97.6% below its estimated GF Value™ of $358.32. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPY:

  • Net Income (Continuing Operations): $-14.76 Mil
  • GF Value™: $358.32 vs. price of $8.67 (97.6% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the ZLDPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma A/S is a Danish biotechnology company that discovers, designs, and develops peptide-based medicines, primarily for metabolic and gastrointestinal diseases. Its pipeline includes dasiglucagon, a glucagon analog approved as Zegalogue for severe hypoglycemia and developed for congenital hyperinsulinism and bihormonal artificial pancreas systems; glepaglutide for short bowel syndrome; and survodutide, a dual GLP-1/glucagon receptor agonist licensed to Boehringer Ingelheim for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis. The company also has partnered programs with other pharmaceutical companies, generating revenue through licensing fees, milestone payments, and royalties. Zealand Pharma is headquartered in Copenhagen, Denmark, and is listed on Nasdaq Copenhagen and, through American Depositary Receipts, on Nasdaq in the United States. Its customers and collaborators are primarily large pharmaceutical companies and healthcare providers in Europe, North America, and other developed markets.
42GF Score

Get the complete analysis for ZLDPY

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.67
Price
$358.32
GF Value